196 related articles for article (PubMed ID: 33196966)
1. The Unintended Consequences of Adverse Event Information on Medicines' Risks and Label Content.
Furlan G; Power D
Pharmaceut Med; 2020 Dec; 34(6):369-380. PubMed ID: 33196966
[TBL] [Abstract][Full Text] [Related]
2. Potential negative impact of informing patients about medication side effects: a systematic review.
Jose J; AlHajri L
Int J Clin Pharm; 2018 Aug; 40(4):806-822. PubMed ID: 30136054
[TBL] [Abstract][Full Text] [Related]
3. Preventing adverse events of chemotherapy by educating patients about the nocebo effect (RENNO study) - study protocol of a randomized controlled trial with gastrointestinal cancer patients.
Quidde J; Pan Y; Salm M; Hendi A; Nilsson S; Oechsle K; Stein A; Nestoriuc Y
BMC Cancer; 2018 Sep; 18(1):916. PubMed ID: 30249191
[TBL] [Abstract][Full Text] [Related]
4. Nocebo phenomena in medicine: their relevance in everyday clinical practice.
Häuser W; Hansen E; Enck P
Dtsch Arztebl Int; 2012 Jun; 109(26):459-65. PubMed ID: 22833756
[TBL] [Abstract][Full Text] [Related]
5. The Influence of Side Effect Information Framing on Nocebo Effects.
Faasse K; Huynh A; Pearson S; Geers AL; Helfer SG; Colagiuri B
Ann Behav Med; 2019 Jun; 53(7):621-629. PubMed ID: 30204841
[TBL] [Abstract][Full Text] [Related]
6. The nocebo effect: a reason for patients' non-adherence to generic substitution?
Weissenfeld J; Stock S; Lüngen M; Gerber A
Pharmazie; 2010 Jul; 65(7):451-6. PubMed ID: 20662309
[TBL] [Abstract][Full Text] [Related]
7. [Which side effects should I inform patients about?].
Reumerman MO; van Puijenbroek EP; Janson JM; van Agtmael MA
Ned Tijdschr Geneeskd; 2020 Jul; 164():. PubMed ID: 32757513
[TBL] [Abstract][Full Text] [Related]
8. Nocebo effects and participant information leaflets: evaluating information provided on adverse effects in UK clinical trials.
Kirby N; Shepherd V; Howick J; Betteridge S; Hood K
Trials; 2020 Jul; 21(1):658. PubMed ID: 32680561
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
[TBL] [Abstract][Full Text] [Related]
10. Introducing the 'Drucebo' effect in statin therapy: a systematic review of studies comparing reported rates of statin-associated muscle symptoms, under blinded and open-label conditions.
Penson PE; Mancini GBJ; Toth PP; Martin SS; Watts GF; Sahebkar A; Mikhailidis DP; Banach M;
J Cachexia Sarcopenia Muscle; 2018 Dec; 9(6):1023-1033. PubMed ID: 30311434
[TBL] [Abstract][Full Text] [Related]
11. The nocebo effect: patient expectations and medication side effects.
Faasse K; Petrie KJ
Postgrad Med J; 2013 Sep; 89(1055):540-6. PubMed ID: 23842213
[TBL] [Abstract][Full Text] [Related]
12. Commentary: Harm, Truth, and the Nocebo Effect.
Ho D
Camb Q Healthc Ethics; 2020 Apr; 29(2):236-245. PubMed ID: 32159482
[TBL] [Abstract][Full Text] [Related]
13. Unintended answer to the nocebo question.
Bauß R
Dtsch Arztebl Int; 2013 Jan; 110(4):58. PubMed ID: 23413389
[No Abstract] [Full Text] [Related]
14. The nocebo effect and its relevance for clinical practice.
Colloca L; Miller FG
Psychosom Med; 2011 Sep; 73(7):598-603. PubMed ID: 21862825
[TBL] [Abstract][Full Text] [Related]
15. Comparative "nocebo effects" in older patients enrolled in cancer therapeutic trials: Observations from a 446-patient cohort.
Foster JC; Le-Rademacher JG; Feliciano JL; Gajra A; Seisler DK; DeMatteo R; Lafky JM; Hurria A; Muss HB; Cohen HJ; Jatoi A
Cancer; 2017 Nov; 123(21):4193-4198. PubMed ID: 28700816
[TBL] [Abstract][Full Text] [Related]
16. Intensive safety monitoring program of antineoplastic medicines: A pilot study in a Portuguese oncology hospital.
Mendes D; Rigueiro G; Silva RS; Penedones A; Alves C; Sousa G; Batel-Marques F
J Oncol Pharm Pract; 2020 Jan; 26(1):133-140. PubMed ID: 31117914
[TBL] [Abstract][Full Text] [Related]
17. The Clinical Implications of Nocebo Effects for Biosimilar Therapy.
Colloca L; Panaccione R; Murphy TK
Front Pharmacol; 2019; 10():1372. PubMed ID: 31849647
[TBL] [Abstract][Full Text] [Related]
18. A systematic review of factors that contribute to nocebo effects.
Webster RK; Weinman J; Rubin GJ
Health Psychol; 2016 Dec; 35(12):1334-1355. PubMed ID: 27657801
[TBL] [Abstract][Full Text] [Related]
19. [Nocebo, informed consent and doctor-patient communication].
Hansen E; Zech N; Benson S
Nervenarzt; 2020 Aug; 91(8):691-699. PubMed ID: 32728796
[TBL] [Abstract][Full Text] [Related]
20. The placebo-nocebo response: controversies and challenges from clinical and research perspective.
Jakovljevic M
Eur Neuropsychopharmacol; 2014 Mar; 24(3):333-41. PubMed ID: 24393653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
